NEOT Neothetics, Inc.

1.15
+0  (0.86%)
Previous Close 1.14
Open 1.17
Price To book 1.14
Market Cap 15.90M
Shares 13,828,000
Volume 152,603
Short Ratio 3.81
Av. Daily Volume 88,229

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 3 endpoints not met December 2015. Phase 2 trial initiated December 23, 2016 with data due late 2Q 2017.
LIPO-202
Reduction of localized fat deposits under the chin (submental fat)
Phase 2 trial planned pending data from submental trial.
LIPO-202
Reduction of central abdominal bulging

Latest News

  1. Neothetics (NEOT) Begins Phase II Study on Lead Candidate
  2. Neothetics Initiates Phase 2 Proof of Concept Trial for LIPO-202 for the Reduction of Submental Subcutaneous Fat
  3. Neothetics Initiates Phase 2 Proof of Concept Trial for LIPO-202 for the Reduction of Submental Subcutaneous Fat
  4. NEOTHETICS, INC. Financials
  5. Neothetics Provides Business Update and Reports Third Quarter 2016 Financial Results
  6. NEOTHETICS, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibits
  7. Neothetics Provides Business Update and Reports Third Quarter 2016 Financial Results
  8. Q3 2016 Neothetics Inc Earnings Release - Before Market Open
  9. Neothetics to Provide a Business Update and Release Third Quarter 2016 Financial Results Thursday, November 10, 2016
  10. Neothetics to Provide a Business Update and Release Third Quarter 2016 Financial Results Thursday, November 10, 2016
  11. NEOTHETICS, INC. Files SEC form 8-K, Termination of a Material Definitive Agreement
  12. Neothetics Provides Business Update and Reports Second Quarter 2016 Financial Results
  13. NEOTHETICS, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibits
  14. Neothetics to Provide a Business Update and Release Second Quarter 2016 Financial Results Thursday, August 11, 2016
  15. NEOTHETICS, INC. Files SEC form 8-K, Submission of Matters to a Vote of Security Holders
  16. NEOTHETICS, INC. Files SEC form 8-K, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard;
  17. 6 Stocks Under $10 Making Big Moves Higher
  18. 5 Breakout Stocks Under $10 Set to Soar
  19. Neothetics Reports First Quarter 2016 Financial Results
  20. NEOTHETICS, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibits

SEC Filings

  1. SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals 17515095
  2. 10-Q - Quarterly report [Sections 13 or 15(d)] 161986057
  3. 8-K - Current report 161986042
  4. 8-K - Current report 161900191
  5. 10-Q - Quarterly report [Sections 13 or 15(d)] 161823046
  6. 8-K - Current report 161823036
  7. 8-K - Current report 161718881
  8. 8-K - Current report 161697534
  9. SC 13G - Statement of acquisition of beneficial ownership by individuals 161646530
  10. 10-Q - Quarterly report [Sections 13 or 15(d)] 161641683